🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

An International Challenge

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million infections annually. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs currently available.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Global Access

Based on data published in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an equal footing with the typical regimen, which uses a dual-drug approach. The trial involved over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals directly involved have expressed hope. Having a one-pill regimen such as this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to alleviate the strain of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.